DavidDTranMDPhD

Neuro-Oncology

Co-Director, USC Brain Tumor Center Chief, Neuro-Oncology Professor of Neurosurgery and Neurology University of Southern California Keck School of Medicine

Join to view full profile

Dr. Tran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tran's full profile

Already have an account?

Office
1520 San Pablo St
Ste 3800
Los Angeles, CA 90033
Phone+1 323-442-5720

Summary

David Tran, MD, is an oncology specialist with a subspecialty in neuro-oncology located in Los Angeles, CA. He completed a fellowship in Hematology and Medical Oncology and a residency in Internal Medicine at the Washington University/B-JH/SLCH Consortium. He also holds a PhD in Biomedical Sciences from the Mayo Clinic College of Medicine. Dr. Tran is a Co-Director at the USC Brain Tumor Center and serves as the Chief of Neuro-Oncology at Keck Medicine. He is experienced in neuro-oncology, tumor immunotherapy, and biomedical research. His recent publications include work on GBM and immunotherapy, and he has participated in clinical trials ranging from breast cancer therapies to glioblastoma treatments. Dr. Tran has been recognized with the CMS Meaningful Use Stage 1 Certification in 2012.

Clinical Expertise

Neuro-oncology, Tumor immunotherapy, Biomedical research

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
Mayo Clinic College of MedicineClass of 2005
Mayo Clinic College of MedicinePhD, Biomedical Sciences, 2003

Certifications & Licensure

CA State Medical License 2023 - 2025
FL State Medical License 2015 - 2023
MO State Medical License 2007 - 2016
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
Completed
Early Phase 1
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Start of enrollment: 2012 Dec 01
Terminated
Phase 4
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 21
COMPLETED
PHASE3
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 Jun 19
TERMINATED
PHASE2
MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2013 Aug 13
Completed
Phase 1
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Start of enrollment: 2016 Dec 19
Terminated
Phase 2
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma Start of enrollment: 2019 May 20
Terminated
Phase 2
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Start of enrollment: 2020 Sep 26
Recruiting
Phase 1, Phase 2
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Start of enrollment: 2018 Feb 23
ACTIVE_NOT_RECRUITING
PHASE2
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Start of enrollment: 2015 Aug 05
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields.
Dongjiang Chen, Son B Le, Harshit Manektalia, Tianyi Liu, Tarun E Hutchinson
Cancer Research. 2025-01-15
A Spatial Interpolation Approach to Assign Magnetic Resonance Imaging-Derived Material Properties for Finite Element Models of Adeno-Associated Virus Infusion Into a R...
Reed Chen, Julian A Rey, Ibrahim S Tuna, David D Tran, Malisa Sarntinoranont
Journal of Biomechanical Engineering. 2024-10-01
2 citations
Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy.
Tianyi Liu, Dan Jin, Son B Le, Dongjiang Chen, Mathew Sebastian
Cancer Immunology Research. 2024-10-01

Press Mentions

USC Receives $6 Million Grant for Pioneering Glioblastoma Gene TherapyFebruary 2nd, 2025
Zai Lab Announces First Quarter 2022 Financial Results and Corporate UpdatesMay 11th, 2022
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 TrialMarch 24th, 2022
Join now to see all